februari
novel
avian
influenza
subtyp
appear
china
result
sever
lower
respiratori
tract
infect
low
pathogen
avian
influenza
viru
emerg
poultri
follow
like
tripl
reassort
event
among
avian
influenza
virus
circul
asian
caus
identifi
ill
poultri
document
human
prior
ref
march
laboratori
confirm
case
death
pandem
influenza
aris
reassort
event
two
influenza
virus
exchang
genet
materi
andor
via
direct
spread
anim
human
influenza
viru
adapt
spread
sustain
humantohuman
transmiss
report
sever
factor
suggest
pandem
potenti
includ
absenc
baselin
immun
human
presenc
genet
marker
associ
human
adapt
ha
gene
substitut
ref
evid
transmiss
direct
contact
airborn
exposur
ferret
model
evid
replic
human
airway
epitheli
cell
also
achiev
higher
peak
viral
titer
human
bronchu
lung
avian
influenza
virus
ref
protect
influenza
primarili
antibodi
mediat
humor
respons
candid
influenza
vaccin
evalu
hemagglutin
inhibit
hai
assay
measur
neutral
antibodi
hai
evalu
antibodi
respons
strainspecif
antigen
site
head
region
influenza
hemagglutinin
ha
titer
tradit
report
correl
protect
season
neutral
antibodi
assay
provid
altern
function
assess
antibodi
respons
capabl
inhibit
infect
cell
current
food
drug
administr
approv
vaccin
prevent
ha
may
intrins
poorli
immunogen
candid
vaccin
histor
gener
limit
immun
poorli
immunogen
live
attenu
influenza
vaccin
laiv
shown
effect
prime
immun
system
inactiv
influenza
similarli
candid
laiv
prime
robust
antibodi
respons
follow
antigen
match
inactiv
dna
vaccin
induc
cellular
humor
immun
manufactur
rapidli
shown
safe
immunogen
vaccin
regimen
influenza
hiv
ebola
sar
west
nile
previous
shown
dna
vaccin
encod
increas
magnitud
qualiti
antibodi
respons
use
prime
vaccin
prior
monoval
inactiv
dna
vaccin
encod
subsequ
develop
shown
provid
protect
lethal
challeng
preclin
test
mice
unpublish
data
herein
report
safeti
immunogen
primeboost
regimen
consist
dna
follow
monoval
inactiv
vaccin
miv
boost
prior
phase
clinic
trial
miv
found
safe
poorli
immunogen
absenc
consequ
evalu
abil
primeboost
regimen
improv
hai
titer
neutral
antibodi
respons
thirti
healthi
individu
enrol
januari
march
last
subject
visit
occur
septemb
fig
demograph
characterist
similar
group
supplement
tabl
vaccinerel
seriou
advers
event
vaccin
well
toler
present
reactogen
mild
moder
sever
supplement
tabl
subject
hai
titer
baselin
two
relat
antigen
strain
consist
naiv
popul
baselin
fig
antibodi
respons
assess
week
week
follow
week
miv
boost
oneway
analysi
varianc
anova
post
hoc
ttest
indic
statist
signific
differ
hai
titer
across
three
group
week
p
anhui
antigen
p
shanghui
antigen
magnitud
frequenc
hai
respons
greater
group
dna
primemiv
boost
group
dnamiv
primemiv
boost
group
miv
primemiv
boost
indic
dna
prime
better
hai
respons
miv
fig
tabl
two
week
follow
boost
peak
gmt
higher
receiv
dna
prime
group
rather
miv
prime
alon
group
differ
reach
signific
group
vs
p
anhui
antigen
group
vs
p
group
vs
p
shanghai
antigen
fig
higher
titer
observ
group
compar
group
differ
signific
either
antigen
five
individu
group
achiev
posit
respons
titer
either
anhui
shanghai
antigen
week
postboost
individu
group
individu
group
achiev
posit
hai
respons
tabl
group
peak
hai
gmt
detect
week
postboost
fig
tabl
group
miv
primemiv
boost
peak
hai
gmt
maintain
week
postboost
although
titer
lower
group
fig
neutral
antibodi
respons
week
postboost
week
significantli
differ
across
three
group
base
oneway
anova
p
although
respons
similar
group
fig
tabl
peak
gmt
significantli
greater
group
receiv
dna
prime
group
p
group
p
compar
group
posit
neutral
antibodi
respons
defin
fourfold
increas
baselin
two
week
follow
boost
group
group
group
achiev
posit
neutral
antibodi
respons
tabl
definit
two
week
follow
boost
highest
neutral
antibodi
respons
identifi
subject
also
achiev
hai
titer
analys
magnitud
respons
comparison
two
group
base
twosampl
ttest
log
transform
datawilcoxon
ranksum
test
also
perform
led
conclus
influenza
public
health
threat
prevent
vaccin
may
need
rapidli
respond
pandem
phase
clinic
trial
novel
dna
vaccin
safe
welltoler
provid
robust
immunogen
prime
vaccin
boost
miv
given
absenc
baselin
immun
human
popul
weak
immunogen
anticip
vaccin
regimen
requir
one
result
consist
assert
dna
vaccin
may
provid
option
prime
immun
system
improv
overal
respons
heterolog
booster
vaccin
provid
greater
magnitud
antibodi
respons
either
vaccin
may
occur
dna
vaccin
prime
differ
popul
cell
proteinbas
vaccin
may
express
trimer
ha
antigen
membran
transduc
cell
may
nativ
structur
ha
miv
durat
locat
antigen
present
may
also
differ
miv
featur
may
lead
bcell
repertoir
differ
specif
broader
expans
antigenspecif
b
cell
could
produc
higher
magnitud
respons
higher
trial
compar
subject
receiv
miv
twice
subject
receiv
dna
prime
vaccin
develop
higher
hai
neutral
antibodi
titer
week
follow
miv
boost
trial
contain
limit
number
subject
result
consist
prior
studi
evalu
similar
regimen
show
dna
prime
miv
vaccin
improv
antibodi
respons
boost
interv
greater
hai
titer
tradit
benchmark
use
correl
protect
season
influenza
one
criterion
licens
season
influenza
howev
remain
unclear
level
hai
titer
associ
protect
novel
influenza
strain
includ
serolog
evalu
laboratoryconfirm
case
china
suggest
robust
antibodi
respons
associ
increas
surviv
one
cohort
patient
infect
survivor
hai
titer
among
fatal
case
hai
titer
ref
contrast
addit
serolog
evalu
patient
confirm
infect
reveal
earli
rapid
induct
neutral
antibodi
rather
hai
correl
improv
clinic
studi
receiv
heterolog
vaccin
regimen
dna
miv
boost
achiev
hai
titer
follow
boost
compar
receiv
miv
prime
alon
boost
hai
titer
subject
compar
anhui
shanghai
strain
subject
receiv
dna
miv
prime
concurr
signific
increas
compar
miv
prime
alon
group
shanghui
strain
vs
p
margin
signific
anhui
strain
vs
p
nevertheless
trend
similar
two
strain
differ
signific
may
occur
due
small
number
subject
involv
studi
previou
studi
indic
older
individu
may
suffer
immunosenesc
follow
studi
contain
small
number
older
subject
upon
enrol
block
random
stratifi
age
prevent
bia
upon
analysi
hai
titer
older
subject
found
compar
younger
subject
suggest
age
effect
vaccin
respons
studi
addit
magnitud
vaccin
induc
neutral
antibodi
respons
greater
subject
receiv
dna
prime
immunogen
dna
prime
neg
impact
coadministr
miv
prime
subject
receiv
dna
miv
prime
concurr
achiev
higher
neutral
antibodi
titer
prior
boost
compar
receiv
dna
prime
suggest
combin
prime
regimen
may
provid
earlier
protect
fig
sinc
emerg
china
sever
candid
vaccin
evalu
human
includ
cellculturederiv
monoval
subunit
vaccin
induc
hai
titer
recipi
follow
iscomatrixadjuv
recombin
viruslik
particl
influenza
vaccin
achiev
hai
titer
receiv
two
monoval
inactiv
vaccin
elicit
hai
titer
recipi
follow
twodos
vaccin
howev
requir
multipl
dose
well
adjuv
achiev
immunogen
vaccin
strategi
describ
still
requir
one
dose
studi
requir
adjuv
includ
dna
vaccin
platform
advantag
dna
vaccin
platform
includ
lack
antivector
immun
plasmid
dna
stabil
speed
eas
manufactur
enhanc
antibodi
tcell
respons
administ
via
needlefre
deliveri
previou
experi
dna
vaccin
show
safe
welltoler
immunogen
prime
vaccin
may
optim
suit
prepandem
scenario
preexist
immun
lack
conclus
administr
dna
miv
vaccin
primeboost
regimen
safe
well
toler
subject
receiv
dna
prime
vaccin
develop
higher
hai
neutral
antibodi
titer
week
follow
miv
boost
small
trial
size
limit
studi
result
agre
previou
studi
involv
dna
prime
although
demonstr
multipl
clinic
trial
mechan
underli
dna
prime
effect
remain
poorli
understood
continu
warrant
evalu
sinc
popul
gener
naiv
provid
uniqu
opportun
evalu
immun
respons
novel
influenza
vaccin
platform
absenc
baselin
immun
evalu
dna
primeinactiv
protein
boost
regimen
divers
b
cell
repertoir
abil
elicit
stemspecif
antibodi
capabl
neutral
heterolog
influenza
viru
strain
provid
addit
insight
complex
immunolog
respons
influenza
vaccin
vrc
singlesit
phase
open
label
random
clinic
trial
perform
nation
institut
health
nih
clinic
center
nation
institut
allergi
infecti
diseas
niaid
vaccin
research
center
vrc
nih
bethesda
md
usa
studi
design
assess
recombin
dna
plasmid
vaccin
administ
alon
monoval
influenza
subunit
virion
vaccin
miv
prime
miv
boost
compar
miv
prime
miv
boost
vrc
design
examin
safeti
toler
immunogen
primeboost
vaccin
regimen
influenza
healthi
adult
age
year
previou
avian
influenza
investig
vaccin
administr
subject
inclus
criteria
also
includ
bodymass
index
lower
normal
baselin
blood
count
normal
liver
renal
function
laboratori
measur
studi
review
approv
niaid
institut
review
board
individu
provid
written
inform
consent
complet
studi
specif
assess
understand
enrol
human
subject
protect
guidelin
conduct
clinic
research
us
depart
health
human
servic
follow
primari
end
point
evalu
safeti
toler
three
primeboost
regimen
primari
immunogen
time
point
week
miv
boost
sampl
size
determin
ensur
good
precis
estim
sever
advers
event
rate
secondari
exploratori
end
point
evalu
antibodi
respons
assess
hai
assay
pseudoviru
neutral
assay
enrol
studi
particip
randomli
assign
per
protocol
design
fig
comput
gener
block
random
stratifi
age
studi
statistician
pharmacist
develop
maintain
random
code
dna
vaccin
manufactur
vrc
leido
biomed
research
inc
frederick
md
vrcniaid
pilot
plant
consist
singl
closedcircular
plasmid
dna
macromolecul
encod
hemagglutinin
protein
influenza
deriv
human
isol
identifi
epiflu
access
global
initi
share
influenza
data
gisaid
epiflu
databas
plasmid
synthes
genescript
piscataway
nj
use
human
prefer
codon
previous
contain
cmvr
promot
previous
plasmid
dna
prepar
current
good
manufactur
practic
mgml
phosphat
buffer
salin
monoval
influenza
subunit
virion
miv
influenza
vaccin
produc
sourc
sanofi
pasteur
inc
swiftwat
pa
vaccin
refer
reassort
use
vaccin
product
provid
center
diseas
control
prevent
cdc
product
complet
follow
procedur
method
use
manufactur
licens
influenza
viru
vaccin
sanofi
pasteur
inc
ha
shanghai
extrem
similar
anhui
two
nucleotid
differ
result
singl
aminoacid
chang
monoval
bulk
concentr
product
bulk
formul
vaccin
fill
oper
perform
licens
facil
vaccin
produc
egg
antibiot
use
manufactur
vaccin
contain
preserv
latex
adjuv
thirteen
male
femal
enrol
vrc
one
three
group
determin
safeti
toler
immunogen
primeboost
vaccin
regimen
influenza
group
receiv
dna
day
miv
week
group
receiv
dna
miv
day
follow
miv
week
group
receiv
miv
day
week
fig
dna
vaccin
mg
given
via
pressur
needlefre
deliveri
system
needlefre
inject
manag
system
miv
vaccin
administ
needl
syring
group
particip
receiv
dna
miv
two
inject
administ
differ
arm
day
dosag
dna
vaccin
miv
vaccin
base
previou
well
previou
human
experi
inactiv
inject
given
intramuscularli
deltoid
assess
local
system
reactogen
day
vaccin
record
advers
event
day
vaccin
code
advers
event
use
medic
dictionari
regulatori
activ
sever
scale
outsid
window
seriou
advers
event
new
chronic
medic
condit
influenza
influenzalik
ill
record
sera
sampl
collect
week
subject
sera
evalu
determin
rel
concentr
neutral
antibodi
evalu
capac
subject
serum
prevent
infect
cell
replic
incompet
hapseudotyp
viru
previous
cell
procur
american
type
cultur
collect
master
work
cell
bank
construct
util
test
cell
test
monthli
mycoplasma
contamin
neutral
activ
quantit
rel
decreas
luciferas
activ
compar
infect
cell
absenc
subject
sera
inhibit
serum
titer
calcul
rel
signal
absenc
sera
use
fiveparamet
curv
fit
hai
assay
done
vbottom
plate
use
four
hemagglutin
unit
viru
hors
red
blood
cell
follow
protocol
establish
collabor
center
refer
research
influenza
center
diseas
control
prevent
usa
http
reassort
virus
ha
na
kindli
provid
limei
chen
center
diseas
control
prevent
influenza
divis
use
hai
assay
laboratori
condit
method
perform
accord
relev
guidelin
regul
primari
outcom
studi
relat
safeti
toler
immunogen
three
primeboost
vaccin
regimen
report
posit
respons
rate
along
exact
confid
interv
comput
pearsonclopp
method
antibodi
respons
data
close
log
normal
distribut
report
magnitud
antibodi
respons
via
geometr
mean
confid
interv
group
comparison
respect
magnitud
respons
base
oneway
anova
twosid
twosampl
ttest
log
transform
data
group
comparison
respect
posit
respons
rate
base
fisher
exact
test
statist
comput
done
statist
softwar
sa
r
underli
data
report
paper
avail
correspond
author
